Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer

We previously reported MELK (maternal embryonic leucine zipper kinase) as a novel therapeutic target for breast cancer. MELK was also reported to be highly upregulated in multiple types of human cancer. It was implied to play indispensable roles in cancer cell survival and indicated its involvement...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Suyoun, Suzuki, Hanae, Miyamoto, Takashi, Takamatsu, Naofumi, Tatsuguchi, Ayako, Ueda, Koji, Kijima, Kyoko, Nakamura, Yusuke, Matsuo, Yo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2012
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681500/
https://www.ncbi.nlm.nih.gov/pubmed/23283305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681500/
https://www.ncbi.nlm.nih.gov/pubmed/23283305

Ejemplares similares